Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial

Objective To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m2) consumed an energy‐reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O‐R, and they consumed the energy‐reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24‐h recall was performed, along with measurements of anthropometric and serum biochemical parameters. Results A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of −6.82 kg (95% CI −8.37 to −5.26) was observed in the O‐R group compared with −3.50 kg (−5.05 to −1.95, P = 0.021) in the placebo group. In contrast, the −6.02 kg (−7.68 to −4.36) orlistat and −4.68 kg (−6.64 to −2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O‐R combination. Conclusions The O‐R combination was the most effective weight loss treatment.